Coronavirus is the biggest public health and economic challenge of our time. In a paper published today in the journal, Aging, Alex Zhavoronkov, PhD, proposes clinical trials for low-dose rapamycin individually and in combination with other geroprotectors to protect the elderly from COVID-19.
